Summary of Use during Lactation

No information is available on the clinical use of durvalumab during breastfeeding. Because durvalumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, durvalumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that mothers not breastfeed during treatment and for 3 months after the last dose of durvalumab.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Durvalumab

CAS Registry Number

1428935-60-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Biological Response Modifiers

Immunologic Adjuvants

Immune Checkpoint Inhibitors

Antibodies, Monoclonal